Senescent cells were supposed to be the "easy" target in aging research—clear them out and extend healthspan. But new research reveals the field is far more complex than anyone imagined, with major clinical trial setbacks forcing scientists to completely rethink their approach.

Some links are affiliate links so we will earn a commission when they are used to purchase products.

In this conversation with Dr. Paul Robbins from the University of Minnesota, we explore the evolving world of senescent cell research and senolytics—drugs designed to clear "zombie" cells from our bodies. Dr. Robbins reveals how recent research shows senescence is far more complex than expected, with different types arising from different stresses. We discuss why Unity Biotech's trials failed, mixed results from fisetin studies, and surprising positive signals from Mayo Clinic trials in patients with high senescent cell burden. He explains why future treatments will require personalized cocktails of different senolytics, the potential of alternative approaches, and why he remains optimistic despite setbacks. Dr. Robbins also shares insights into next-generation compounds his lab is developing and hints at positive clinical trial results coming soon.

🌐Links in this video

APERS & TRIALS

Fisetin at the ITP

Astaxanthin and meclizine extend lifespan in UM-HET3 male mice; fisetin, SG1002 (hydrogen sulfide donor), dimethyl fumarate, mycophenolic acid, and 4-phenylbutyrate do not significantly affect lifespan in either sex at the doses and schedules used

https://pmc.ncbi.nlm.nih.gov/articles/PMC10828146/

Bone strength trial

Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans

https://clinicaltrials.gov/study/NCT04313634

Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study (SToMP-AD)

https://www.clinicaltrials.gov/study/NCT04685590

Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability

https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(23)00046-4/fulltext

Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age

https://pmc.ncbi.nlm.nih.gov/articles/PMC9924942/

Seeking Health supplements: 10% discount code Richard10 https://crrnt.app/SEEK/-dm0MyrQ, Histamine Nutrients https://crrnt.app/SEEK/EpM7paAO

AX3 Life Astaxanthin 20% discount code MODERN20 https://tinyurl.com/2t3w26nw

https://www.choosemuse.com

All Muse devices 15% discount code MODERN https://choosemuse.com/MODERN

Stemregen 15% discount Code MODERN https://tinyurl.com/45z968yr (Only available in the US)

Renue by Science all 10% discount with code MHS https://renuebyscience.com/

Nuchido Time+ 20% discount of first purchase with code MODERN20 https://nuchido.com/MODERN

If you would like to support our channel please consider signing up on patreon https://patreon.com/ModernHealthspan

You can also find us on YouTube at https://www.youtube.com/c/modernhealthspan